書籍詳細

[1] 病理診断

P.10 掲載の参考文献

• 1) Oschlies I, Klapper W, Zimmermann M et al.: Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 107:4047-4052, 2006

• 2) Lamant I, McCarthy K, d'Amore E et al.: Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol 29:4669-76, 2011

• 3) Oschlies I, Burkhardt B, Chassagne -Clement C et al.: Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol 35:836-844, 2011
  pubmed

[2] 免疫学的診断

P.31 掲載の参考文献

• 1) Campana D, Behm FG: Immunophenotyping of leukemia. J Immunol Methods 243:59-75, 2000.
  pubmed

• 2) 日本臨床検査標準協議会血液検査標準化検討委員会フローサイトメトリーワーキンググループ: フローサイトメトリーによる造血器腫瘍細胞表面抗原検査に関するガイドライン. 日本臨床検査標準協議会会誌 18:69-107, 2003 (http://www.jccls.org/techreport/06.html).

• 3) Coustan-Smith E, Mullighan CG, Onciu M et al.: Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10:147-156, 2009.

[3] 細胞遺伝学的および分子生物学的診断

P.45 掲載の参考文献

• 1) Kluin PM, Harris NL, Stein H, Leoncini L, Raphael M et al.: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). IARC Lyon, France, 2008.

• 2) 金井正光: 第13章 染色体検査・遺伝子関連検査. 臨床検査法提要. 金原出版, 2010, p1113〜1215.

• 3) Shaffer LG, Slovak ML, Campbell LJ: An International System of Human Cytogenetic Nomenclature. Basel, Karger, 2009.

• 4) 阿部達生: 第3章 分子遺伝学の手技と遺伝子異常の解析. 3-a分子生物学的診断技術. 3-b FISH法. 造血器腫瘍アトラス. 日本医事新報社, 2009, p60〜107.

• 5) 滝智彦, 林泰秀: 染色体検査結果とキメラ遺伝子検査結果の食い違い症例の検討. 日本小児血液学会雑誌 23:310-314, 2009.
  Medical*Online

• 6) Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J et al.: New insights to the MLL recombinome of acute leukemias. Leukemia 23:1490-1499, 2009.

• 7) Romana SP, Radford-Weiss I, Ben Abdelali R, Schluth C, Petit A et al.: Groupe Francophone de Cytogenetique Hematologique. NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogenetique Hematologique. Leukemia 20:696-706, 2006.
  pubmed

• 8) Pui CH, Carroll AJ, Raimondi SC, Land VJ, Crist WM et al.: Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line. Blood 75:1170-1177, 1990.
  pubmed

• 9) Fujino H, Fujita N, Hamamoto K, Oobu S, Kita M et al.: Ring/marker chromosome derived from chromosome 7 in childhood acute megakaryoblastic leukemia with monosomy 7. Int J Hematol 92:386-390, 2010.
  pubmed

[4] PCRによるMRD測定

P.51 掲載の参考文献

• 1) Yokota S et al.: Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 77:331-339, 1991.
  pubmed

• 2) Grunewald K et al.: Molecular genetic analysis of DNA obtained from fixed, air dried or paraffin embedded sources. Ann. Hematol 62:108-114, 1991.
  pubmed

• 3) Pongers-Willemse M J et al.: Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 13:110-118, 1999.

• 4) Beishuizen A et al.: Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual disease. Leukemia 11:2200-2207, 1997.

• 5) Seriu T et al.: Improved detection of minimal residual leukemia through modifications of polymerase chain reaction analysis based on clonospecific T cell receptor junctions. Leukemia 9:316-320, 1995.
  pubmed

• 6) van Dongen JJ, Langerak AW, Bruggemann M et al.: Design and stadardization of PCR primers and protocols for detection of immunogloblin and T-cell receptor gene recombinants in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257-2317, 2003.

• 7) Langerak AW, Szczepanski T, Ban der Burg M et al.: Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia 11:2192-2199, 1997.

• 8) 五十嵐隆, 菊地陽・編: 小児科臨床ピクシス10 小児白血病診療. 中山書店, 2009, p25-26.

• 9) Heid CA, Stevens J, Livak KJ et al.: Real-time quantitative PCR. Genome Res 6:986-994, 1996.
  pubmed

• 10) van der Velden VH et al.: MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time q Methods Mol Biol 538:115-150, 2009.

• 11) van der Velden VH, Cazzaniga G, Schrauder A et al.: analysis of minimal residual disease by Ig/TCR gene rearrangements: guideline for interpretation of real-time quantitative PCR data. Leukemia 21:604-611, 2007.

索引 (和文索引, 英文索引)

P.59 掲載の参考文献

• 1) Coustan-Smith E et al.: Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 100(7):2399-2402, 2002.
  pubmed

• 2) Coustan-Smith E et al.: Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96(8):2691-2696, 2000.
  pubmed

• 3) Coustan-Smith E et al.: Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 100(1):52-58, 2002.
  pubmed

• 4) Gaipa G et al.: Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia 19(1):49-56, 2005.

• 5) Dworzak MN et al.: CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia 18(4):703-708, 2004.

• 6) Dworzak MN et al.: Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 99(6):1952-1958, 2002.
  pubmed